Iterum Therapeutics PLC (NAS:ITRM)
$ 1.05 -0.01 (-0.94%) Market Cap: 23.84 Mil Enterprise Value: 33.60 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Iterum Therapeutics PLC Phase 3 Topline Data Conference Call Transcript

Jan 30, 2024 / 01:30PM GMT
Release Date Price: $1.46 (-11.73%)
Operator

Hello, everybody, and welcome to the Iterum Therapeutics P3 REASSURE clinical trial results. After the speakers' remarks, there will be a question and answer session. (Operator Instructions)

It's now my pleasure to turn the conference over to Louise Barrett, Senior Vice President, Legal Affairs.

Louise Barrett Iterum Therapeutics PLC;SVP
Legal Affairs

Thank you, Drew. Good morning and welcome to the Iterum Therapeutics Phase 3 REASSURE clinical trial results conference call. A press release with our top end results was issued earlier this morning and can be found on our website.

The press release also the link to the webcast. And if you're not using the webcast, the slides will be referencing are available on our website, www.iterumtx.com under the heading Investors and Events and Presentations. And also filed as an exhibit to our current report on Form 8-K filed this morning with the SEC.

We are joined this morning by our Chief Executive Officer,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot